Announces Date of Annual General Meeting,
Appointment of Directors, and Interim Chief Financial Officer
VANCOUVER, BC, March 12,
2024 /PRNewswire/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSX: NUMI) (OTCQX:
NUMIF), a mental health care company advancing traditional and
innovative behavioral health treatments with a focus on safe,
evidence-based novel therapies, announces that it has amended the
date of its Annual General Meeting to May
21, 2024, for shareholders as of the record date of
April 2, 2024. The AGM was moved to
facilitate the retirement of Ed
Garner and the appointment of a director to replace him.
Details of the meeting will be distributed to shareholders of
record on or about April 15,
2024.
Director changes
The Company also announces Edwin
Garner's retirement from its Board of Directors. Mr. Garner
has been a member of the Numinus Board since May 2020 and served on the Company's Audit and
Compensation Committees.
"Ed has been a board member of Numinus since we first listed and
has provided valuable counsel over that time," said Payton Nyquvest, Founder, Chair, and CEO of
Numinus. We thank him for his service."
The Board additionally announces the appointment of Donna Wilson and Donna
Wong as directors effectively immediately.
Donna Wilson brings to Numinus
over two decades of executive management experience in the public
and private sectors. Her work experience includes executive roles
in people management and strategy for the British Columbia
Provincial Health Services Authority, LifeLabs Canada, the
Vancouver Olympic Organizing Committee, and WorkSafe BC. She serves
on various non-profit and charitable boards.
Donna Wong has extensive
experience in corporate governance, risk management, and public
company corporate finance, primarily in the healthcare and
technology sectors. She is the Chief Financial Officer of Novari
Health, a private SaaS company focused on providing digital access
to care solutions to hospitals and health networks, and the
Managing Director of OnPoint Advisors. She has held various
executive roles in finance, including at Reunion Neuroscience,
Field Trip Health and Wellness, and ViXS Systems. In these roles,
she established the necessary corporate infrastructure to scale and
go public on Nasdaq, TSX and TSX-V. She has experience on various
non-profit and charitable boards. She currently serves on the Audit
& Finance Committee of the Royal Ottawa Institute of Mental
Health and Research and holds a CPA designation.
Both directors will stand for election at the upcoming Annual
General Meeting.
"We are thrilled to welcome both Donna
Wilson and Donna Wong to the
Board, where their experience in strategy, corporate finance,
corporate governance, and people management will be a significant
resource to Numinus as we work to expand our business and take
advantage of the opportunities available to us to address the
growing need for innovative mental health care," added Mr.
Nyquvest.
Interim CFO
Melony Valleau has been appointed
as Numinus' Interim CFO. A CPA, Melony brings to Numinus over two
decades of working with Nasdaq-listed companies, financial
reporting and maintaining SEC compliance. Melony has served as the
Chief Accounting Officer at MedMen Enterprises, the CFO of BAR
Education, and the Controller at Stem Holdings. Numinus' current
CFO, Nikhil Handa, will step down
from his position to pursue new opportunities. However, he will
remain with the company to assist with the transfer of
responsibilities.
"We welcome Melony to the team as our Interim CFO," stated
Payton Nyquvest. "Her U.S. corporate
finance and capital markets experience will be valuable and align
with our plans to increase our presence with patients and the
investment community."
"In his time with Numinus, Nikhil was key in helping us make the
crucial decisions to improve efficiencies and put us on the path to
profitability. We thank him for his strategic insights and
dedication and wish him well in his future endeavours," added Mr.
Nyquvest.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be
well through the development and delivery of innovative mental
health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model – including psychedelic research and
clinic care – is at the forefront of a transformation aimed at
healing rather than managing symptoms for depression, anxiety,
trauma, pain and substance use. At Numinus, we are leading the
integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-looking
statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements, including but not limited to the
appointment of new directors, the election or re-election of
directors at this and subsequent AGMs, and the risks set forth in
our annual information form dated November
29, 2023, and available on SEDAR at
www.sedarplus.ca. Forward-looking statements are based on
estimates and opinions of management at the date the statements are
made. Numinus does not undertake any obligation to update
forward-looking statements even if circumstances or management's
estimates or opinions should change except as required by
applicable laws. Investors should not place undue reliance on
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/numinus-wellness-provides-corporate-update-302085967.html
SOURCE Numinus Wellness Inc.